GlassScriptPhysician profile
Glenn Litman
NPI 1770544181
$5,813.33
in general payments reported to CMS, 2019-2025
27 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,068 · 2023: $1,454 · 2024: $1,879 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,744.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,095.45 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $937.05 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $760.72 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $433.29 | 2022-2025 | |
| Lilly USA, LLC | $431.72 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $389.74 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $292.87 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $254.13 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $184.17 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $138.73 | 2022-2023 | Nuzyra |
| Exact Sciences Corporation | $130.21 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.77 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Kowa Pharmaceuticals America, INC. | $109.39 | 2022-2023 | Livalo, Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $97.15 | 2022 | |
| Janssen Pharmaceuticals, INC | $74.74 | 2023-2024 | Xarelto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $68.72 | 2022-2023 | Loreev Xr, Sertraline Hcl, Gralise |
| Edwards Lifesciences Corporation | $55.98 | 2025 | Sapien 3 Ultra Resilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.66 | 2023-2024 | Xifaxan |
| Corium, LLC | $30.58 | 2022 | |
| Acerus Pharmaceuticals Corporation | $24.16 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.65 | 2023 | Horizant |
| Amarin Pharma, INC. | $20.43 | 2022 | |
| Tonix Medicines, INC. | $19.62 | 2025 | Tonmya |
| Otsuka America Pharmaceutical, INC. | $18.15 | 2023 | Rexulti |
| Amneal Pharmaceuticals LLC | $15.14 | 2025 | Crexont |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.94 | 2025 | Caplyta |
| Althera Pharmaceuticals LLC | $11.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Litman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.